Drug intelligence / Profile preview

GPC3-1XX CAR T cells with IL1RAP CCR

Development stage
Preclinical
Lead developer
Baylor College of Medicine
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01

Overview

GPC3-1XX CAR T cells with IL1RAP CCR are an investigational **IF-BETTER-gated CAR-T-cell therapy** for hepatocellular carcinoma. The engineered T cells use a glypican-3-directed CAR containing the GC33 single-chain variable fragment and a calibrated 1XX signaling module, which preserves GPC3-restricted tumor-cell killing while aiming to improve functional persistence. A separate interleukin-1 receptor accessory protein-directed chimeric costimulatory receptor supplies conditional costimulation after IL1RAP engagement, increasing T-cell proliferation, repeated-stimulation fitness, tumor infiltration, and antitumor activity, particularly against tumors with low GPC3 expression. The construct was reported preclinically by Columbia University investigators.

Other names
GPC3-1XX + IL1RAP-CCR T cellsGPC3-1XX CAR + IL1RAP CCR T cellsGPC3-1XX CAR T cells with IL1RAP CCRGPC-3-1XX CAR T cells with IL1RAP CCRGPC 3-1XX CAR T cells with IL1RAP CCRGPC3-1XX CAR/IL1RAP CCR T cells
02

Targets

IL1RAP (Interleukin 1 receptor accessory protein)GPC3 (Glypican-3)

Beyond the preview

Go deeper on GPC3-1XX CAR T cells with IL1RAP CCR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPC3-1XX CAR T cells with IL1RAP CCR.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call